Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 114

1.

Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas.

Montgomery RC, Hoffman JP, Riley LB, Rogatko A, Ridge JA, Eisenberg BL.

Ann Surg Oncol. 1997 Oct-Nov;4(7):551-6.

PMID:
9367020
[PubMed - indexed for MEDLINE]
2.

Intensified adjuvant therapy for pancreatic and periampullary adenocarcinoma: survival results and observations regarding patterns of failure, radiotherapy dose and CA19-9 levels.

Abrams RA, Grochow LB, Chakravarthy A, Sohn TA, Zahurak ML, Haulk TL, Ord S, Hruban RH, Lillemoe KD, Pitt HA, Cameron JL, Yeo CJ.

Int J Radiat Oncol Biol Phys. 1999 Jul 15;44(5):1039-46.

PMID:
10421536
[PubMed - indexed for MEDLINE]
3.

Prognostic value of CA 19-9 levels in patients with carcinoma of the pancreas treated with radiotherapy.

Katz A, Hanlon A, Lanciano R, Hoffman J, Coia L.

Int J Radiat Oncol Biol Phys. 1998 May 1;41(2):393-6.

PMID:
9607356
[PubMed - indexed for MEDLINE]
4.

Biliary CA 19-9 values correlate with the risk of hepatic metastases in patients with adenocarcinoma of the pancreas.

Montgomery RC, Hoffma JP, Ross EA, Riley LB, Ridge JA, Eisenberg BL.

J Gastrointest Surg. 1998 Jan-Feb;2(1):28-35.

PMID:
9841965
[PubMed - indexed for MEDLINE]
5.

The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.

Kang CM, Kim JY, Choi GH, Kim KS, Choi JS, Lee WJ, Kim BR.

J Surg Res. 2007 Jun 1;140(1):31-5. Epub 2007 Apr 9.

PMID:
17418869
[PubMed - indexed for MEDLINE]
6.

Prognostic value of CA 19-9 serum course in pancreatic cancer.

Safi F, Schlosser W, Falkenreck S, Beger HG.

Hepatogastroenterology. 1998 Jan-Feb;45(19):253-9.

PMID:
9496523
[PubMed - indexed for MEDLINE]
7.

CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent.

Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E, Rosemurgy A.

J Gastrointest Surg. 2009 Feb;13(2):349-53. doi: 10.1007/s11605-008-0696-3. Epub 2008 Oct 30.

PMID:
18972170
[PubMed - indexed for MEDLINE]
8.

Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma.

Berger AC, Meszoely IM, Ross EA, Watson JC, Hoffman JP.

Ann Surg Oncol. 2004 Jul;11(7):644-9. Epub 2004 Jun 14.

PMID:
15197014
[PubMed - indexed for MEDLINE]
9.

Clinical usefulness of CA-19-9 in pancreatic carcinoma.

Nakao A, Oshima K, Nomoto S, Takeda S, Kaneko T, Ichihara T, Kurokawa T, Nonami T, Takagi H.

Semin Surg Oncol. 1998 Jul-Aug;15(1):15-22.

PMID:
9671952
[PubMed - indexed for MEDLINE]
10.

Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer.

Hata S, Sakamoto Y, Yamamoto Y, Nara S, Esaki M, Shimada K, Kosuge T.

Ann Surg Oncol. 2012 Feb;19(2):636-41. doi: 10.1245/s10434-011-2020-9. Epub 2011 Aug 24.

PMID:
21863360
[PubMed - indexed for MEDLINE]
11.

Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms.

Safi F, Schlosser W, Kolb G, Beger HG.

J Gastrointest Surg. 1997 Mar-Apr;1(2):106-12.

PMID:
9834336
[PubMed - indexed for MEDLINE]
12.

[Prediction of prognosis of patients with pancreatic adenocarcinoma with curative intent resection by means of histologic grade and pathologic N stage].

Soriano-Izquierdo A, Adet AC, Gallego R, Miquel R, Castells A, Pellisé M, Nadal C, López-Boado MA, Piqué JM, Gascón P, Conill C, Bombí A, Fernández-Cruz L, Maurel J, Navarro S.

Med Clin (Barc). 2009 Feb 14;132(5):163-71. doi: 10.1016/j.medcli.2008.07.012. Epub 2009 Feb 7. Spanish.

PMID:
19211081
[PubMed - indexed for MEDLINE]
13.

Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma.

Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V, Villa E.

Cancer. 2009 Jun 15;115(12):2630-9. doi: 10.1002/cncr.24302.

PMID:
19353729
[PubMed - indexed for MEDLINE]
Free Article
14.

Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy?

Turrini O, Schmidt CM, Moreno J, Parikh P, Matos JM, House MG, Zyromski NJ, Nakeeb A, Pitt HA, Lillemoe KD.

J Gastrointest Surg. 2009 Oct;13(10):1791-7. doi: 10.1007/s11605-009-0916-5. Epub 2009 May 21.

PMID:
19459018
[PubMed - indexed for MEDLINE]
15.

Prognostic value of serum CA 19-9 levels in pancreatic adenocarcinoma.

Tian F, Appert HE, Myles J, Howard JM.

Ann Surg. 1992 Apr;215(4):350-5.

PMID:
1348409
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

Serum CA19-9 is a significant predictor among preoperative parameters for early recurrence after resection of pancreatic adenocarcinoma.

Sugiura T, Uesaka K, Kanemoto H, Mizuno T, Sasaki K, Furukawa H, Matsunaga K, Maeda A.

J Gastrointest Surg. 2012 May;16(5):977-85. doi: 10.1007/s11605-012-1859-9. Epub 2012 Mar 13.

PMID:
22411488
[PubMed - indexed for MEDLINE]
17.

Increased levels of both carbohydrate antigen 19-9 and duke pancreatic monoclonal antigen type 2 reflect postoperative prognosis in patients with pancreatic carcinoma.

Shibata K, Iwaki K, Kai S, Ohta M, Kitano S.

Pancreas. 2009 Aug;38(6):619-24. doi: 10.1097/MPA.0b013e3181a53ee7.

PMID:
19436235
[PubMed - indexed for MEDLINE]
18.

Prognostic value of CA 19-9 level in resectable pancreatic adenocarcinoma.

Rudnicki J, Agrawal AK, Grzebieniak Z, Zukrowski P, Zyśko D, Jelen M, Kielan W, Sebastian M, Słonina J, Marek G, Duda-Barcik Ł.

Folia Histochem Cytobiol. 2010 Jan;48(2):249-61. doi: 10.2478/v10042-010-0034-y.

PMID:
20675282
[PubMed - indexed for MEDLINE]
Free Article
19.

The lymph node ratio is the strongest prognostic factor after resection of pancreatic cancer.

Riediger H, Keck T, Wellner U, zur Hausen A, Adam U, Hopt UT, Makowiec F.

J Gastrointest Surg. 2009 Jul;13(7):1337-44. doi: 10.1007/s11605-009-0919-2. Epub 2009 May 6.

PMID:
19418101
[PubMed - indexed for MEDLINE]
20.

Prognosis of malignant intraductal papillary mucinous tumours of the pancreas after surgical resection. Comparison with pancreatic ductal adenocarcinoma.

Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, Barthet M, O'Toole D, Rufat P, Partensky C, Cuillerier E, Lévy P, Belghiti J, Ruszniewski P.

Gut. 2002 Nov;51(5):717-22.

PMID:
12377813
[PubMed - indexed for MEDLINE]
Free PMC Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk